BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

7048

524669

HESTERBIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

HESTER BIOSCIENCES LTD performance

Today’s low

Today’s high

₹ 1766.00 ₹ 1862.10
₹ 1782.90

52 week low

52 week high

₹ 1242.95 ₹ 3379.00
₹ 1782.90

Open Price

₹ 1862.10

Prev. Close

₹ 1838.10

Volume (Shares)

5446.00

Total traded value

₹ 97.09

Upper Circuit

₹ 2205.70

Lower Circuit

₹ 1470.50

info

HESTER BIOSCIENCES LTD Share Price Update

As of the latest trading session, HESTER BIOSCIENCES LTD share price is currently at ₹ 1771, which is down by ₹ -67.09 from its previous closing. Today, the stock has fluctuated between ₹ 1766.00 and ₹ 1862.10. Over the past year, HESTER BIOSCIENCES LTD has achieved a return of 13.12 %. In the last month alone, the return has been 23.44 %. Read More...

HESTER BIOSCIENCES LTD fundamentals


  • Market cap (Cr)

    1,506.56

  • P/E Ratio (TTM)

    52.85

  • Beta

    0.73

  • Book Value / share

    382.47

  • Return on equity

    8.98%

  • EPS (TTM)

    34.84

  • Dividend yield

    0.33%

  • Net profit/quarter (Cr)

    4.44

info icon alternate text
  • Market cap (Cr)

    1,505.71

  • P/E Ratio (TTM)

    52.85

  • Beta

    0.60

  • Book Value / share

    382.47

  • Return on equity

    8.98%

  • EPS (TTM)

    34.84

  • Dividend yield

    0.33%

  • Net profit/quarter (Cr)

    4.44

info icon alternate text

HESTER BIOSCIENCES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 62.83
Operating Expense 57.64
Net Profit 4.44
Net Profit Margin (%) 7.06
Earnings Per Share (EPS) 5.22
EBITDA 10.32
Effective Tax Rate (%) 31.58
Particulars SEP 2024 (Values in Cr)
Revenue 73.50
Operating Expense 62.37
Net Profit 9.34
Net Profit Margin (%) 12.70
Earnings Per Share (EPS) 10.97
EBITDA 16.07
Effective Tax Rate (%) 25.24
Particulars JUN 2024 (Values in Cr)
Revenue 73.47
Operating Expense 63.22
Net Profit 8.43
Net Profit Margin (%) 11.47
Earnings Per Share (EPS) 9.91
EBITDA 14.56
Effective Tax Rate (%) 25.37
Particulars MAR 2024 (Values in Cr)
Revenue 72.87
Operating Expense 63.85
Net Profit 7.43
Net Profit Margin (%) 10.19
Earnings Per Share (EPS) 8.74
EBITDA 13.62
Effective Tax Rate (%) 27.27
Particulars DEC 2023 (Values in Cr)
Revenue 65.51
Operating Expense 57.87
Net Profit 6.48
Net Profit Margin (%) 9.89
Earnings Per Share (EPS) 7.61
EBITDA 12.55
Effective Tax Rate (%) 24.85
Particulars MAR 2024 (Values in Cr)
Revenue 285.16
Operating Expense 252.68
Net Profit 27.16
Net Profit Margin (%) 9.52
Earnings Per Share (EPS) 31.93
EBITDA 51.59
Effective Tax Rate (%) 26.05
Particulars MAR 2023 (Values in Cr)
Revenue 254.00
Operating Expense 215.40
Net Profit 32.34
Net Profit Margin (%) 12.73
Earnings Per Share (EPS) 38.02
EBITDA 60.21
Effective Tax Rate (%) 26.36
Particulars MAR 2022 (Values in Cr)
Revenue 219.35
Operating Expense 170.75
Net Profit 39.52
Net Profit Margin (%) 18.01
Earnings Per Share (EPS) 46.45
EBITDA 65.22
Effective Tax Rate (%) 25.79
Particulars MAR 2021 (Values in Cr)
Revenue 208.48
Operating Expense 150.07
Net Profit 39.90
Net Profit Margin (%) 19.13
Earnings Per Share (EPS) 46.90
EBITDA 68.36
Effective Tax Rate (%) 27.16
Particulars MAR 2020 (Values in Cr)
Revenue 169.43
Operating Expense 131.12
Net Profit 31.22
Net Profit Margin (%) 18.42
Earnings Per Share (EPS) 36.70
EBITDA 55.64
Effective Tax Rate (%) 24.27
Particulars MAR 2024 (Values in Cr)
Book Value / Share 343.00
ROE % 7.41
ROCE % 8.74
Total Debt to Total Equity 0.91
EBITDA Margin 22.63
Particulars MAR 2023 (Values in Cr)
Book Value / Share 328.82
ROE % 10.39
ROCE % 9.01
Total Debt to Total Equity 0.93
EBITDA Margin 26.37
Particulars MAR 2022 (Values in Cr)
Book Value / Share 305.61
ROE % 16.17
ROCE % 13.29
Total Debt to Total Equity 0.69
EBITDA Margin 31.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 268.38
ROE % 16.16
ROCE % 16.44
Total Debt to Total Equity 0.54
EBITDA Margin 32.67
Particulars MAR 2020 (Values in Cr)
Book Value / Share 236.36
ROE % 16.38
ROCE % 16.20
Total Debt to Total Equity 0.56
EBITDA Margin 33.70
Particulars MAR 2024 (Values in Cr)
Book Value / Share 367.59
ROE % 8.98
ROCE % 8.51
Total Debt to Total Equity 0.49
EBITDA Margin 18.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 343.70
ROE % 11.53
ROCE % 11.52
Total Debt to Total Equity 0.51
EBITDA Margin 23.70
Particulars MAR 2022 (Values in Cr)
Book Value / Share 315.54
ROE % 15.62
ROCE % 17.26
Total Debt to Total Equity 0.27
EBITDA Margin 29.74
Particulars MAR 2021 (Values in Cr)
Book Value / Share 279.28
ROE % 18.11
ROCE % 23.26
Total Debt to Total Equity 0.14
EBITDA Margin 32.79
Particulars MAR 2020 (Values in Cr)
Book Value / Share 238.72
ROE % 16.32
ROCE % 19.73
Total Debt to Total Equity 0.23
EBITDA Margin 32.84
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 15.30
Total Assets 662.34
Total Liabilities 662.34
Total Equity 302.87
Share Outstanding 8506865
Price to Book Ratio 3.78
Return on Assets (%) 2.85
Return on Capital (%) 3.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.81
Total Assets 669.96
Total Liabilities 669.96
Total Equity 288.54
Share Outstanding 8506865
Price to Book Ratio 4.42
Return on Assets (%) 3.97
Return on Capital (%) 4.78
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.20
Total Assets 562.16
Total Liabilities 562.16
Total Equity 267.39
Share Outstanding 8506865
Price to Book Ratio 8.61
Return on Assets (%) 6.99
Return on Capital (%) 8.03
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 21.26
Total Assets 411.04
Total Liabilities 411.04
Total Equity 235.95
Share Outstanding 8506865
Price to Book Ratio 6.86
Return on Assets (%) 8.37
Return on Capital (%) 10.11
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 23.53
Total Assets 386.60
Total Liabilities 386.60
Total Equity 206.49
Share Outstanding 8506865
Price to Book Ratio 3.88
Return on Assets (%) 7.54
Return on Capital (%) 9.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 4.96
Total Assets 549.54
Total Liabilities 549.54
Total Equity 312.71
Share Outstanding 8506865
Price to Book Ratio 3.78
Return on Assets (%) 4.94
Return on Capital (%) 6.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 5.96
Total Assets 545.81
Total Liabilities 545.81
Total Equity 292.38
Share Outstanding 8506865
Price to Book Ratio 4.42
Return on Assets (%) 5.92
Return on Capital (%) 7.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.98
Total Assets 424.44
Total Liabilities 424.44
Total Equity 268.43
Share Outstanding 8506865
Price to Book Ratio 8.61
Return on Assets (%) 9.31
Return on Capital (%) 10.12
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.24
Total Assets 282.01
Total Liabilities 282.01
Total Equity 237.58
Share Outstanding 8506865
Price to Book Ratio 6.86
Return on Assets (%) 14.14
Return on Capital (%) 15.74
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 5.19
Total Assets 277.19
Total Liabilities 277.19
Total Equity 203.08
Share Outstanding 8506865
Price to Book Ratio 3.88
Return on Assets (%) 11.26
Return on Capital (%) 12.89
Particulars MAR 2024 (Values in Cr)
Net Income 31.95
Cash from Operations 59.80
Cash from Investing -22.65
Cash from Financing -26.04
Net change in Cash -0.40
Free Cash Flow 84.19
Particulars MAR 2023 (Values in Cr)
Net Income 40.15
Cash from Operations 31.70
Cash from Investing -76.99
Cash from Financing 41.75
Net change in Cash -11.59
Free Cash Flow 109.46
Particulars MAR 2022 (Values in Cr)
Net Income 53.50
Cash from Operations 25.82
Cash from Investing -116.58
Cash from Financing 111.53
Net change in Cash 3.48
Free Cash Flow 121.53
Particulars MAR 2021 (Values in Cr)
Net Income 50.10
Cash from Operations 71.99
Cash from Investing -38.37
Cash from Financing -18.21
Net change in Cash -2.26
Free Cash Flow 112.73
Particulars MAR 2020 (Values in Cr)
Net Income 41.32
Cash from Operations 47.70
Cash from Investing -74.47
Cash from Financing 18.74
Net change in Cash -17.11
Free Cash Flow 121.20
Particulars MAR 2024 (Values in Cr)
Net Income 36.73
Cash from Operations 53.84
Cash from Investing -20.63
Cash from Financing -24.07
Net change in Cash -1.89
Free Cash Flow 76.21
Particulars MAR 2023 (Values in Cr)
Net Income 43.92
Cash from Operations 41.42
Cash from Investing -71.96
Cash from Financing 41.37
Net change in Cash 2.77
Free Cash Flow 114.07
Particulars MAR 2022 (Values in Cr)
Net Income 53.25
Cash from Operations 32.34
Cash from Investing -110.58
Cash from Financing 94.96
Net change in Cash 0.28
Free Cash Flow 123.01
Particulars MAR 2021 (Values in Cr)
Net Income 54.78
Cash from Operations 54.59
Cash from Investing -3.72
Cash from Financing -41.32
Net change in Cash -3.94
Free Cash Flow 58.84
Particulars MAR 2020 (Values in Cr)
Net Income 41.22
Cash from Operations 37.17
Cash from Investing -21.33
Cash from Financing -1.39
Net change in Cash 3.09
Free Cash Flow 45.57
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

HESTER BIOSCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1782.90 -3.00 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 1868.50
  • 26 Days 1715.80
  • 10 Days 1826.40
  • 50 Days 1720.30
  • 12 Days 1807.40
  • 100 Days 1855.60
  • 20 Days 1743.40
  • 200 Days 1980.80
1867.03 PIVOT

First Support

1797.07

First Resistance

1908.07

Second Support

1756.03

Second Resistance

1978.03

Third Support

1686.07

Third Resistance

2019.07

RSI

59.56

ADX

35.44

MACD

91.52

Williams % R

-45.15

Commodity Channel Index (CCI)

79.42

Date

2025-04-29

Week

7319.00

Same Day

5541.00

Month

14972.00

1 Year

0.73

3 Year

0.50

Over 1 Month

23.44%

down

Over 1 Year

13.12%

down

Over 3 Months

-12.27%

down

Over 3 Years

-11.06%

down

Over 6 Months

-20.51%

down

Over 5 Years

6.13%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

HESTER BIOSCIENCES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
45.37%
Promoter Holdings
53.73%
FII
0.87%
DII
0.01%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Rajiv Dinesh Gandhi 890397.0 (10.47%) Shareholding of Promoter and Promoter Group
Sanjiv Dinesh Gandhi 697820.0 (8.2%) Shareholding of Promoter and Promoter Group
Nina Rajiv Gandhi 696340.0 (8.19%) Shareholding of Promoter and Promoter Group
Shaila Bhupendra Gandhi 491300.0 (5.78%) Shareholding of Promoter and Promoter Group
Ravin Gandhi 403320.0 (4.74%) Shareholding of Promoter and Promoter Group
Bela Gandhi 400635.0 (4.71%) Shareholding of Promoter and Promoter Group
Bhupendra Vithaldas Gandhi 399100.0 (4.69%) Shareholding of Promoter and Promoter Group
Kuntal Hasmukhlal Shah 269897.0 (3.17%) Public Shareholding
Biolink Healthcare Limited 248838.0 (2.93%) Shareholding of Promoter and Promoter Group
Manish Jain 245248.0 (2.88%) Public Shareholding
Anup Chandravadan Kapadia 228354.0 (2.68%) Shareholding of Promoter and Promoter Group
Darshna Dinesh Kapadia 153600.0 (1.81%) Public Shareholding
Vinay Shah 108900.0 (1.28%) Public Shareholding
Manish Jain 104869.0 (1.23%) Public Shareholding
Manish Prataprai Gandhi 100000.0 (1.18%) Public Shareholding
Jagrut Prataprai Gandhi 100000.0 (1.18%) Public Shareholding
Sandeep Shantilal Gala 89890.0 (1.06%) Public Shareholding
Hester Coatings Llp 64000.0 (0.75%) Shareholding of Promoter and Promoter Group
Hester Diagnostics Private Limited 24000.0 (0.28%) Shareholding of Promoter and Promoter Group
Hetal Sanjiv Gandhi 19590.0 (0.23%) Shareholding of Promoter and Promoter Group
Yash Rajiv Gandhi 7250.0 (0.09%) Shareholding of Promoter and Promoter Group
Bhupendra Vithaldas Gandhi Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

HESTER BIOSCIENCES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Sep 2023 8.0 Final 14 Sep 2023 Equity shares
11 Aug 2022 10.0 Final 12 Aug 2022 Equity shares
05 Aug 2021 10.0 Final 07 Aug 2021 Equity shares
27 Aug 2020 6.6 Final 29 Aug 2020 Equity shares
18 Jul 2019 7.0 Final 20 Jul 2019 Equity shares
09 Nov 2018 2.0 Interim 2 12 Nov 2018 Equity shares
30 Aug 2018 2.0 Interim 1 31 Aug 2018 Equity shares
02 Aug 2018 6.0 Final 04 Aug 2018 Equity shares
16 Nov 2017 4.0 Interim 17 Nov 2017 Equity shares
20 Jul 2017 2.3 Final 22 Jul 2017 Equity shares
03 Nov 2016 3.0 Interim 04 Nov 2016 Equity shares
21 Jul 2016 1.1 Final 23 Jul 2016 Equity shares
17 Mar 2016 3.0 Interim 18 Mar 2016 Equity shares
10 Sep 2015 3.1 Final 12 Sep 2015 Equity shares
18 Sep 2014 2.0 Final 20 Sep 2014 Equity shares
07 Aug 2013 2.0 Final 10 Aug 2013 Equity shares
27 Aug 2012 1.0 Final 28 Aug 2012 Equity shares
25 Aug 2011 3.5 Final 27 Aug 2011 Equity shares
22 Jul 2010 3.0 Final 24 Jul 2010 Equity shares
13 Aug 2009 2.5 Final 15 Aug 2009 Equity shares
21 Aug 2008 2.5 Final 23 Aug 2008 Equity shares
06 Sep 2007 2.0 Final 08 Sep 2007 Equity shares
06 Jun 2005 0.0 Final 08 Jun 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Sep 2012 27 Sep 2012 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Sep 2023 8.0 Final 14 Sep 2023 Equity shares
11 Aug 2022 10.0 Final 12 Aug 2022 Equity shares
05 Aug 2021 10.0 Final 07 Aug 2021 Equity shares
27 Aug 2020 6.6 Final 29 Aug 2020 Equity shares
18 Jul 2019 7.0 Final 20 Jul 2019 Equity shares
09 Nov 2018 2.0 Interim 2 12 Nov 2018 Equity shares
30 Aug 2018 2.0 Interim 1 31 Aug 2018 Equity shares
02 Aug 2018 6.0 Final 04 Aug 2018 Equity shares
16 Nov 2017 4.0 Interim 17 Nov 2017 Equity shares
20 Jul 2017 2.3 Final 22 Jul 2017 Equity shares
03 Nov 2016 3.0 Interim 04 Nov 2016 Equity shares
21 Jul 2016 1.1 Final 23 Jul 2016 Equity shares
17 Mar 2016 3.0 Interim 18 Mar 2016 Equity shares
10 Sep 2015 3.1 Final 12 Sep 2015 Equity shares
18 Sep 2014 2.0 Final 20 Sep 2014 Equity shares
07 Aug 2013 2.0 Final 10 Aug 2013 Equity shares
27 Aug 2012 1.0 Final 28 Aug 2012 Equity shares
25 Aug 2011 3.5 Final 27 Aug 2011 Equity shares
22 Jul 2010 3.0 Final 24 Jul 2010 Equity shares
13 Aug 2009 2.5 Final 15 Aug 2009 Equity shares
21 Aug 2008 2.5 Final 23 Aug 2008 Equity shares
06 Sep 2007 2.0 Final 08 Sep 2007 Equity shares
06 Jun 2005 0.0 Final 08 Jun 2005 Equity shares
Ex-Date Ex-Bonus Ratio
29 Sep 2012 27 Sep 2012 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

HESTER BIOSCIENCES LTD Share Price

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. The Company was incorporated in April, 1987 and is principally engaged in manufacturing of Poultry vaccines and Large Animal Vaccines and trading of Poultry and Large animal and Petcare health products having its manufacturing set up at Meda Adraj Village, Mehsana District, Gujarat.

The Company engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.

The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium.

The company's own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation.

During 1996-97, company successfully implemented veterinary vaccine and commercial production has begun.

The company received licenses for producing 10 additional poultry vaccines. It signed a manufacturing agreement with Sinsui Inc for producing poultry vaccines.

In 2003, Hester was appointed as the exclusive Indian distributor by BIOPHARM of Czech Republic, for their coccidiosis vaccine - LIVACOX.

Hester commenced business with Merial in the 3rd quarter of the financial year by importing poultry vaccines from them in 2004-05 and therefore, name of Company was changed from HESTER PHARMACEUTICALS LIMITED to HESTER BIOSCIENCES LIMITED. The Company embarked on an expansion program, to increase its capacity from 1200 million doses to 4800 million doses, which was commenced in January 2006. The expansion project and the new expanded capacity went on-stream in March 2007. The distribution network within India was made functional with company managed depots at Pune, Bangalore, Coimbatore, Hyderabad and Chandigarh, having state-of-art cold store facilities to maintain the cold chain. Distribution costs were further cut by embarking on the use of company owned refrigerated vans for deliveries all across India.

In January 2010, the company re-launched the freeze dried MD Vaccine after 5 years. A JV was set-up in Nepal to facilitate manufacture of specific animal vaccines for international markets in 2011 for a project which costed Rs 15 crores. New technology was acquired. The Company signed a technology transfer agreement with Indian Veterinary Research Institute for acquiring technology to manufacture PPR and Sheep Pox vaccines in 2011.

Company re-launched the bivalent Marek's Disease Live vaccine for the poultry, containing HVT & SB1 strains in 2012-13. It operationalised large animal vaccines division in Mar' 15. During the financial year 2014-15, Gujarat Agrofarm Limited became a wholly owned subsidiary of the Company.

During financial year 2015-16, three wholly owned subsidiary Companies namely Gujarat Agrofarm Limited, Diavetra Lifesciences Private Limited and Hester Biosciences (Mauritius) Limited got merged with Company through a Scheme of Arrangement effective on 8 December 2015. Accordingly, the Company allotted and listed its 65 Equity Shares pursuant to Scheme of Arrangement vide order passed by Hon'ble High Court of Gujarat dated 8 December 2015 and the said Shares were listed at NSE Limited and BSE Limited in March, 2016. Leruarua Vetcare (Proprietary) Limited, incorporated in Botswana became an Associate Company with 49% stake of the Company and Innoves Animal Health Private Limited ceases to be an Associate Company due to transfer of shareholding of the Company in FY 2015-16.

The Nepal unit completed trial operations and began commercial manufacturing in November, 2016. Leruarua Vetcare (Proprietary) Limited, Botswana ceases to be an Associate Company due to buyback of entire shareholding by the Associate Company during the FY 2016-17. The Company held 65% stake in subsidiary Company, Hester Biosciences Nepal Private Limited (HBNPL) and consequently, HBNPL became a subsidiary of Hester Biosciences Limited (Parent Company) during FY 2016-17.

During the year 2017-18, Company acquired 54.80% in the capital of Texas Laboratories, a firm having a business place at Mehsana Distt. of Gujarat. In June 2017, Texas Laboratories converted into Private Limited Company namely, Texas Lifesciences Private Limited. Further, the Company incorporated 100% wholly-owned subsidiary, Hester Biosciences Africa Limited in Tanzania.

During the year 2018-19, Hester Biosciences Limited incorporated 100% wholly-owned subsidiary Hester Biosciences Kenya Limited in Kenya. The Company commissioned the vaccine manufacturing plant at Tanzania in 2021. It launched the Petcare Division in 2022.

In FY 2022, Company acquired 50% stake in Tanzania based Thrishool Exim Limited, company of vaccines and animal health products in Tanzania. It launched 3 products for anti-infective, specialty nutrition, parasiticides and grooming. It commenced production of Newcastle Disease and Gumboro vaccines for poultry, and PPR and Contagious Bovine Pleuropneumonia (CBPP) vaccines for large animals.

Parent organization Indian Private
NSE symbol HESTERBIO
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Hester Biosciences Ltd?

Answer Field

The share price of Hester Biosciences Ltd for NSE is ₹ 1771 and for BSE is ₹ 1770.

What is the Market Cap of Hester Biosciences Ltd?

Answer Field

The market cap of Hester Biosciences Ltd for NSE is ₹ 15,06.56 Cr. and for BSE is ₹ 15,05.71 Cr. as of now.

What is the 52 Week High and Low of Hester Biosciences Ltd?

Answer Field

The 52 Week High and Low of Hester Biosciences Ltd for NSE is ₹ 3379.00 and ₹ 1242.95 and for BSE is ₹ 3375.45 and ₹ 1246.75.

How to Buy Hester Biosciences Ltd share?

Answer Field

You can trade in Hester Biosciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Hester Biosciences Ltd?

Answer Field

The 1 year returns on the stock has been 13.12%.

What is the Current Share Price of Hester Biosciences Ltd?

Answer Field

Hester Biosciences Ltd share price is for NSE ₹ 1771 & for BSE ₹ 1770 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Hester Biosciences Ltd Share?

Answer Field

The market cap of Hester Biosciences Ltd for NSE ₹ 15,06.56 & for BSE ₹ 15,05.71 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Hester Biosciences Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Hester Biosciences Ltd share is 52.85.

What is the PB ratio of Hester Biosciences Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Hester Biosciences Ltd share is 382.47.

How to Buy Hester Biosciences Ltd Share?

Answer Field

You can trade in Hester Biosciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Hester Biosciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Hester Biosciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Hester Biosciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|